Related Experiment Video
Updated: May 9, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
RP11-738E22.3 promotes hepatocellular carcinoma progression by inhibiting autophagy and apoptosis via MAPK/ERK/mTOR
Yihong Chen1, Erya Hu2, Shiqi Tang3
1Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, Hunan, China.
Abstract:
Hepatocellular carcinoma (HCC) is an extraordinarily heterogeneous tumor that poses a hazard to millions of people globally. Long intergenic noncoding RNAs (lincRNAs) have been recognized as key regulators influencing prognosis of HCC patients. However, their underlying mechanisms in HCC warrant further investigation. The role of the unreported lincRNA RP11-738E22.3 in HCC is still unknown. In this research, differentially expressed lincRNAs were identified using Arraystar long noncoding RNA (lncRNA) microarray sequencing, and the expression levels of RP11-738E22.3 were measured by RT-qPCR and FISH. The impact of RP11-738E22.3 on HCC cell autophagy, apoptosis, xenograft tumor growth, and metastasis were investigated in both in vitro and in vivo experiments. Furthermore, RNA sequencing, dual-luciferase reporter assays, and rescue tests were carried out to clarify its molecular process. We found that RP11-738E22.3 was substantially overexpressed in HCC tissues and linked to poor prognosis and unfavorable clinicopathological characteristics in HCC patients. Functionally, by upregulating FBXO6, an activator of the MAPK/ERK/mTOR signaling, RP11-738E22.3 stimulated HCC migration and proliferation in vitro and in vivo. Mechanically, RP11-738E22.3 regulated FBXO6 expression by competitively binding to miR-504-3p and miR-3135b, thereby activating the MAPK/ERK/mTOR pathway to suppress autophagy and apoptosis in HCC. In conclusion, lincRNA RP11-738E22.3 is a novel and promising biomarker for HCC progression, exerting its oncogenic effects through the inhibition of autophagy and apoptosis via activation of MAPK/ERK/mTOR signaling. Targeting RP11-738E22.3 may offer new therapeutic opportunities for HCC treatment.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...